SCHEDULE 13G/A: BlackRock Amends Passive Stake in Apellis Pharmaceuticals, Holding 4.5% of Common Stock

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.5% passive ownership stake in Apellis Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 5,598,572 shares of Apellis Pharmaceuticals, Inc. Common Stock.
• This represents 4.5% of the class of securities outstanding.
• BlackRock holds sole voting power over 5,405,388 shares and sole dispositive power over 5,598,572 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Apellis Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing (Schedule 13G) disclosing a passive ownership stake. It contains no positive or negative news about the issuer's operations or financial performance, nor does it suggest any strategic changes. Its sentiment is neutral as it simply reports a compliance-driven update.

Positives

• BlackRock, a major institutional investor, maintains a significant, albeit passive, stake in Apellis Pharmaceuticals, Inc.
• The investment is stated to be in the ordinary course of business, indicating a routine portfolio holding rather than an activist position.

Negatives

• The filing itself does not contain negative information about Apellis Pharmaceuticals, Inc. as it is a disclosure of ownership by BlackRock.

Risks

• The document explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, mitigating potential governance risks from this specific holding.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding Apellis Pharmaceuticals, Inc.'s future performance or strategic direction. It solely reports BlackRock's current ownership stake.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Spencer Fleming, Managing Director of BlackRock, Inc.)

Industry Context

This filing reflects a routine disclosure by BlackRock, one of the world's largest asset managers, regarding its passive investment holdings in a publicly traded pharmaceutical company. Such disclosures are standard practice for institutional investors crossing certain ownership thresholds, providing transparency into significant market participants' positions.

Comparison to Industry Standards

• This is a standard Schedule 13G filing, which is a routine disclosure for institutional investors like BlackRock when their beneficial ownership of a company's stock falls below or reaches certain thresholds (typically below 5% for passive investors, or an amendment to a previous filing).
• The filing adheres to SEC regulations for passive investment reporting.
• No specific comparable companies, projects, or results are mentioned within the document itself, as it focuses solely on BlackRock's ownership in Apellis.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding BlackRock's passive, non-controlling stake in Apellis Pharmaceuticals, Inc.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this ownership disclosure.

Key Dates

Keywords

Apellis Pharmaceuticals, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, Pharmaceuticals, Biotechnology, SEC Filing